June 22, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3628
Attn: | Ms. Laura Crotty |
| | |
Re: | Castle Biosciences, Inc. (the “Company”) – Request for Acceleration |
| | Registration Statement on Form S-1 (File No. 333-239354) |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), and as representatives of the several underwriters of the Company’s proposed public offering of common shares, we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, as amended, requesting effectiveness for 4:30 p.m. Eastern Time on June 24, 2020, or as soon thereafter as is practicable.
Pursuant to Rule 460 of the Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the shares of common stock, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We, the undersigned, as representatives of the several underwriters, have complied and will continue to comply, and we have been informed by the participating underwriters that they have complied and will continue to comply, with the provisions of Rule 15c2-8 of the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
| | Very truly yours, |
| | |
| | SVB Leerink LLC |
| | Robert W. Baird & Co. Incorporated |
| | |
| | As representatives of the several Underwriters |
| | |
| | |
| | By: SVB Leerink LLC |
| | By: | /s/ Ryan Lindquist |
| | Name: Ryan Lindquist |
| | Title: Managing Director |
| | By: Robert W. Baird & Co. Incorporated |
| | By: | /s/ Ryan Engelhardt |
| | Name: Ryan Engelhardt |
| | Title: Managing Director |
[Signature Page to Acceleration Request Letter]
